novladex ?

[snake]

I'm post cycle for five weeks and my source is finally coming through with novladex. I'm using it to try and reduce gyno from previous Human Chorionic Gonadotropin (HCG) and (regrettably) Pro hormone use.
will the novla affect the gains I have made? will it help reduce estrogen fat? and will it at all be affective in reducing Gyno?
Any info and experiences would be great thx

 

[hhajdo]

Nolva will not affect your gains.

Many people use it post cycle to increase their test/LH...

It can definitely reduce your gyno.

It will not affect your body composition unless you diet.

 

[hhajdo]

Dtsch Med Wochenschr 1984 Nov 2;109(44):1678-82 Related Articles, Links


[Testosterone and estradiol levels in male gynecomastia. Clinical and endocrine findings during treatment with tamoxifen]

[Article in German]

Eversmann T, Moito J, von Werder K.

Oestradiol-(E2) levels in serum were significantly higher in a group of 91 males with gynaecomastia than in a control group. The levels were highest in patients with testicular tumour, hyperprolactinaemia and idiopathic gynaecomastia. In gynaecomastia of puberty and primary or secondary hypogonadism, the E2 level was within normal limits, but the testosterone/oestradiol ratio was significantly reduced. Tamoxifen, at a daily dose of 20 mg, was administered over 2-4 months to 16 patients with gynaecomastia. Of twelve patients with painful gynaecomastia ten became painfree. Gynaecomastia regressed partially or completely in 14 patients, in only 2 was it unchanged. There was no recurrence of gynaecomastia after discontinuing tamoxifen. Side-effects did not occur. It is concluded that tamoxifen is a promising alternative to the surgical treatment of gynaecomastia.

 

[StoneColdNTO]

Dtsch Med Wochenschr 1984 Nov 2;109(44):1678-82 Related Articles, Links


[Testosterone and estradiol levels in male gynecomastia. Clinical and endocrine findings during treatment with tamoxifen]

[Article in German]

Eversmann T, Moito J, von Werder K.

Oestradiol-(E2) levels in serum were significantly higher in a group of 91 males with gynaecomastia than in a control group. The levels were highest in patients with testicular tumour, hyperprolactinaemia and idiopathic gynaecomastia. In gynaecomastia of puberty and primary or secondary hypogonadism, the E2 level was within normal limits, but the testosterone/oestradiol ratio was significantly reduced. Tamoxifen, at a daily dose of 20 mg, was administered over 2-4 months to 16 patients with gynaecomastia. Of twelve patients with painful gynaecomastia ten became painfree. Gynaecomastia regressed partially or completely in 14 patients, in only 2 was it unchanged. There was no recurrence of gynaecomastia after discontinuing tamoxifen. Side-effects did not occur. It is concluded that tamoxifen is a promising alternative to the surgical treatment of gynaecomastia.

That is a very promising study !!